Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

13. Referanser

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. (2008). Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA, 299(16), 1914-1921. https://doi.org/10.1001/jama.299.16.1914

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. G. (2010). Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer, 116(17), 4007-4013. https://doi.org/10.1002/cncr.25188

Akbari, R. P., Paty, P. B., Guillem, J. G., Weiser, M. R., Temple, L. K., Minsky, B. D., . . . Wong, W. D. (2004). Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Diseases of the Colon and Rectum, 47(7), 1136-1144. https://doi.org/10.1007/s10350-004-0548-5

Alam, N. N., White, D. A., Narang, S. K., Daniels, I. R., & Smart, N. J. (2016). Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II/III). Colorectal Disease, 18(2), 135-146. https://doi.org/10.1111/codi.13215

Alberta Provincial Gastrointestinal Tumour Team. (2013). Anal canal cancer (Clinical practice guideline GI-001 version 4). Alberta: Alberta health Services. Hentet fra http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gi001-anal-canal.pdf

Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., . . . Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 103(2), 210-216. https://doi.org/10.1002/cpt.911

Arana, R., Fléjou, J. F., Si-Mohamed, A., Bauer, P., & Etienney, I. (2015). Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Disease, 17(11), 965-972. https://doi.org/10.1111/codi.12951

Bahng, A. Y., Dagan, A., Bruner, D. W., & Lin, L. L. (2012). Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer. International Journal of Radiation Oncology, Biology, Physics, 82(2), 667-673. https://doi.org/10.1016/j.ijrobp.2010.10.071

Balamucki, C. J., Zlotecki, R. A., Rout, W. R., Newlin, H. E., Morris, C. G., Kirwan, J. M., . . . Mendenhall, W. M. (2011). Squamous cell carcinoma of the anal margin: the university of Florida experience. American Journal of Clinical Oncology, 34(4), 406-410. https://doi.org/10.1097/COC.0b013e3181e9c0c0

Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., . . . Pierart, M. (1997). Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Journal of Clinical Oncology, 15(5), 2040-2049. https://doi.org/10.1200/jco.1997.15.5.2040

Ben-Josef, E., Moughan, J., Ajani, J. A., Flam, M., Gunderson, L., Pollock, J., . . . Willett, C. (2010). Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. Journal of Clinical Oncology, 28(34), 5061-5066. https://doi.org/10.1200/jco.2010.29.1351

Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y. J., Ciombor, K. K., . . . Freedman-Cass, D. A. (2018). Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 16(7), 852-871. https://doi.org/10.6004/jnccn.2018.0060

Bentzen, A. G., Balteskard, L., Wanderås, E. H., Frykholm, G., Wilsgaard, T., Dahl, O., & Guren, M. G. (2013). Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncologica, 52(4), 736-744. https://doi.org/10.3109/0284186x.2013.770599

Bentzen, A. G., Guren, M. G., Vonen, B., Wanderas, E. H., Frykholm, G., Wilsgaard, T., . . . Balteskard, L. (2013). Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiotherapy and Oncology, 108(1), 55-60. https://doi.org/10.1016/j.radonc.2013.05.037

Bentzen, A. G., Guren, M. G., Wanderas, E. H., Frykholm, G., Tveit, K. M., Wilsgaard, T., . . . Balteskard, L. (2012). Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. International Journal of Radiation Oncology, Biology, Physics, 83(2), e173-180. https://doi.org/10.1016/j.ijrobp.2011.12.062

Bese, N. S., Hendry, J., & Jeremic, B. (2007). Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. International Journal of Radiation Oncology, Biology, Physics, 68(3), 654-661. https://doi.org/10.1016/j.ijrobp.2007.03.010

Bhuva, N. J., Glynne-Jones, R., Sonoda, L., Wong, W. L., & Harrison, M. K. (2012). To PET or not to PET? That is the question. Staging in anal cancer. Annals of Oncology, 23(8), 2078-2082. https://doi.org/10.1093/annonc/mdr599

Bilimoria, K. Y., Bentrem, D. J., Rock, C. E., Stewart, A. K., Ko, C. Y., & Halverson, A. (2009). Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Diseases of the Colon and Rectum, 52(4), 624-631. https://doi.org/10.1007/DCR.0b013e31819eb7f0

Brogden, D. R. L., Walsh, U., Pellino, G., Kontovounisios, C., Tekkis, P., & Mills, S. C. (2021). Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review. International Journal of Colorectal Disease, 36(2), 213-226. https://doi.org/10.1007/s00384-020-03740-6

Brown, E., Cray, A., Haworth, A., Chander, S., Lin, R., Subramanian, B., & Ng, M. (2015). Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. Journal of medical radiation sciences, 62(2), 99-107. https://doi.org/10.1002/jmrs.99

Brown, G., Richards, C. J., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., Dallimore, N. S., & Williams, G. T. (2003). Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology, 227(2), 371-377. https://doi.org/10.1148/radiol.2272011747

Bruland, O., Fluge, O., Immervoll, H., Balteskard, L., Myklebust, M., Skarstein, A., & Dahl, O. (2008). Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer, 98(7), 1264-1273. https://doi.org/10.1038/sj.bjc.6604285

Cacheux, W., Lievre, A., De La Rochefordiere, A., Dieumegard, B., Cvitkovic, F., Labib, A., . . . Buecher, B. (2012). Chemotherapy in the treatment of anal canal carcinoma. Digestive and Liver Disease, 44(10), 803-811. https://doi.org/10.1016/j.dld.2012.04.013

Cancer in Norway 2019: cancer incidence, mortality, survival and prevalence in Norway. (2020). Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2019/cin_report.pdf

Castor, M., da Silva, H. J., Gondim Martins, D. B., & de Mello, R. J. (2012). HPV and precancerous lesions of anal canal in women: systematic review. International Journal of Colorectal Disease, 27(3), 271-276. https://doi.org/10.1007/s00384-011-1298-1

Chan, R. J., Webster, J., Chung, B., Marquart, L., Ahmed, M., & Garantziotis, S. (2014). Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer, 14, 53. https://doi.org/10.1186/1471-2407-14-53

Chuong, M. D., Freilich, J. M., Hoffe, S. E., Fulp, W., Weber, J. M., Almhanna, K., . . . Shridhar, R. (2013). Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointestinal Cancer Research, 6(2), 39-45.

Clark, M. A., Hartley, A., & Geh, J. I. (2004). Cancer of the anal canal. Lancet Oncology, 5(3), 149-157. https://doi.org/10.1016/s1470-2045(04)01410-x

Coffey, K., Beral, V., Green, J., Reeves, G., & Barnes, I. (2015). Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years. British Journal of Cancer, 112(9), 1568-1574. https://doi.org/10.1038/bjc.2015.89

Cox, J. D., Stetz, J., & Pajak, T. F. (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics, 31(5), 1341-1346. https://doi.org/10.1016/0360-3016(95)00060-c

Croke, J. M., & El-Sayed, S. (2012). Multidisciplinary management of cancer patients: chasing a shadow or real value? An overview of the literature. Current Oncology (Toronto, Ont.), 19(4), e232-238. https://doi.org/10.3747/co.19.944

Dale, J. E., Sebjornsen, S., Leh, S., Rosler, C., Aaserud, S., Moller, B., . . . Dahl, O. (2017). Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncologica, 56(1), 81-87. https://doi.org/10.1080/0284186x.2016.1244356

Daling, J. R., Madeleine, M. M., Johnson, L. G., Schwartz, S. M., Shera, K. A., Wurscher, M. A., . . . McDougall, J. K. (2004). Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer, 101(2), 270-280. https://doi.org/10.1002/cncr.20365

Dasgupta, T., Rothenstein, D., Chou, J. F., Zhang, Z., Wright, J. L., Saltz, L. B., . . . Goodman, K. A. (2013). Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiotherapy and Oncology, 107(2), 189-194. https://doi.org/10.1016/j.radonc.2013.03.012

Deenen, M. J., Dewit, L., Boot, H., Beijnen, J. H., Schellens, J. H., & Cats, A. (2013). Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. International Journal of Radiation Oncology, Biology, Physics, 85(5), e201-207. https://doi.org/10.1016/j.ijrobp.2012.12.008

Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., . . . Schellens, J. H. (2016). Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology, 34(3), 227-234. https://doi.org/10.1200/jco.2015.63.1325

DeFoe, S. G., Beriwal, S., Jones, H., Rakfal, S., Heron, D. E., Kabolizadeh, P., . . . Lalonde, R. (2012). Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clinical Oncology (Royal College of Radiologists), 24(6), 424-431. https://doi.org/10.1016/j.clon.2011.09.014

DeFoe, S. G., Kabolizadeh, P., Heron, D. E., & Beriwal, S. (2013). Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy. Oncology, 85(1), 1-7. https://doi.org/10.1159/000348387

Dutta, S. W., Alonso, C. E., Waddle, M. R., Khandelwal, S. R., Janowski, E. M., & Trifiletti, D. M. (2018). Squamous cell carcinoma of the rectum: Practice trends and patient survival. Cancer medicine, 7(12), 6093-6103. https://doi.org/10.1002/cam4.1893

Dyson, T., & Draganov, P. V. (2009). Squamous cell cancer of the rectum. World Journal of Gastroenterology, 15(35), 4380-4386.

Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., & Trotti, A. (2010). American Joint Committee on Cancer. Ajcc cancer staging handbook: from the AJCC cancer staging manual (7. utg.). New York: Springer

Eng, C., Chang, G. J., You, Y. N., Das, P., Rodriguez-Bigas, M., Xing, Y., . . . Wolff, R. A. (2014). The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget, 5(22), 11133-11142. https://doi.org/10.18632/oncotarget.2563

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. (1996). Lancet, 348(9034), 1049-1054.

Erridge, S. C., Kerr, G. R., Downing, D., Duncan, W., & Price, A. (2002). The effect of overall treatment time on the survival and toxicity of radical radiotherapy for cervical carcinoma. Radiotherapy and Oncology, 63(1), 59-66. https://doi.org/10.1016/s0167-8140(02)00012-9

Faivre, C., Rougier, P., Ducreux, M., Mitry, E., Lusinchi, A., Lasser, P., . . . Eschwege, F. (1999). Carcinome epidermoide metastatique de l'anus: etude retrospective de l'efficacite de l'association de 5-fluoro-uracile en perfusion continue et de cisplatine [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bulletin du Cancer, 86(10), 861-865.

Fish, R., Sanders, C., Adams, R., Brewer, J., Brookes, S. T., DeNardo, J., . . . Renehan, A. G. (2018). A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. The lancet. Gastroenterology & hepatology, 3(12), 865-873. https://doi.org/10.1016/s2468-1253(18)30264-4

Fox, P. A., Nathan, M., Francis, N., Singh, N., Weir, J., Dixon, G., . . . Bower, M. (2010). A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS, 24(15), 2331-2335. https://doi.org/10.1097/QAD.0b013e32833d466c

Franco, P., Arcadipane, F., Ragona, R., Mistrangelo, M., Cassoni, P., Munoz, F., . . . Ricardi, U. (2016). Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. British Journal of Radiology, 89(1060), 20150832.

Fuchshuber, P. R., Rodriguez-Bigas, M., Weber, T., & Petrelli, N. J. (1997). Anal canal and perianal epidermoid cancers. Journal of the American College of Surgeons, 185(5), 494-505.

Gautier, M., Brochard, C., Lion, A., Henno, S., Mallet, A. L., Bodere, A., . . . Siproudhis, L. (2016). High-grade anal intraepithelial neoplasia: Progression to invasive cancer is not a certainty. Digestive and Liver Disease, 48(7), 806-811. https://doi.org/10.1016/j.dld.2016.03.011

Gilbert, D. C., Serup-Hansen, E., Linnemann, D., Hogdall, E., Bailey, C., Summers, J., . . . Thomas, G. J. (2016). Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. British Journal of Cancer, 114(2), 134-137. https://doi.org/10.1038/bjc.2015.448

Gilbert, D. C., Williams, A., Allan, K., Stokoe, J., Jackson, T., Linsdall, S., . . . Summers, J. (2013). p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiotherapy and Oncology, 109(1), 146-151. https://doi.org/10.1016/j.radonc.2013.08.002

Glover, M., Smerdon, G. R., Andreyev, H. J., Benton, B. E., Bothma, P., Firth, O., . . . Yarnold, J. (2016). Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial. Lancet Oncology, 17(2), 224-233. https://doi.org/10.1016/s1470-2045(15)00461-1

Glynne-Jones, R., Meadows, H., Wan, S., Gollins, S., Leslie, M., Levine, E., . . . Sebag-Montefiore, D. (2008). EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. International Journal of Radiation Oncology, Biology, Physics, 72(1), 119-126. https://doi.org/10.1016/j.ijrobp.2007.12.012

Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014a). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 111(3), 330-339. https://doi.org/10.1016/j.radonc.2014.04.013

Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014b). Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25 Suppl 3, iii10-20. https://doi.org/10.1093/annonc/mdq171

Glynne-Jones, R., Sebag-Montefiore, D., Adams, R., McDonald, A., Gollins, S., James, R., . . . Jitlal, M. (2011). "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). International Journal of Radiation Oncology, Biology, Physics, 81(5), 1488-1494. https://doi.org/10.1016/j.ijrobp.2010.07.1995

Glynne-Jones, R., Sebag-Montefiore, D., Meadows, H. M., Cunningham, D., Begum, R., Adab, F., . . . Kadalayil, L. (2017). Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncology, 18(3), 347-356. https://doi.org/10.1016/s1470-2045(17)30071-2

Goh, V., Gollub, F. K., Liaw, J., Wellsted, D., Przybytniak, I., Padhani, A. R., & Glynne-Jones, R. (2010). Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? International Journal of Radiation Oncology, Biology, Physics, 78(3), 715-721. https://doi.org/10.1016/j.ijrobp.2009.08.055

Goldman, S., Auer, G., Erhardt, K., & Seligson, U. (1987). Prognostic significance of clinical stage, histologic grade, and nuclear DNA content in squamous-cell carcinoma of the anus. Diseases of the Colon and Rectum, 30(6), 444-448.

Guerra, G. R., Kong, C. H., Warrier, S. K., Lynch, A. C., Heriot, A. G., & Ngan, S. Y. (2016). Primary squamous cell carcinoma of the rectum: An update and implications for treatment. World Journal of Gastrointestinal Surgery, 8(3), 252-265. https://doi.org/10.4240/wjgs.v8.i3.252

Guidelines for the management of anal cancer. I. (2007). Guidelines for the management of colorectal cancer (3. utg., s. 68-95). London: The Association of Coloproctology of Great Britain and Ireland. Hentet fra http://www.acpgbi.org.uk/content/uploads/2007-CC-Management-Guidelines.pdf

Gunderson, L. L., Moughan, J., Ajani, J. A., Pedersen, J. E., Winter, K. A., Benson, A. B., 3rd, . . . Willett, C. G. (2013). Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. International Journal of Radiation Oncology, Biology, Physics, 87(4), 638-645. https://doi.org/10.1016/j.ijrobp.2013.07.035

Gunderson, L. L., Winter, K. A., Ajani, J. A., Pedersen, J. E., Moughan, J., Benson, A. B., 3rd, . . . Willett, C. G. (2012). Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. Journal of Clinical Oncology, 30(35), 4344-4351. https://doi.org/10.1200/jco.2012.43.8085

Guren, M. G., Aagnes, B., Nygard, M., Dahl, O., & Moller, B. (2019). Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. Clinical Colorectal Cancer, 18(1), e96-e103. https://doi.org/10.1016/j.clcc.2018.10.001

Han, K., Cummings, B. J., Lindsay, P., Skliarenko, J., Craig, T., Le, L. W., . . . Kim, J. (2014). Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. International Journal of Radiation Oncology, Biology, Physics, 90(3), 587-594. https://doi.org/10.1016/j.ijrobp.2014.06.061

Hatfield, P., Cooper, R., & Sebag-Montefiore, D. (2008). Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. International Journal of Radiation Oncology, Biology, Physics, 70(2), 419-424. https://doi.org/10.1016/j.ijrobp.2007.06.072

Hemminki, K., Liu, X., Ji, J., Sundquist, J., & Sundquist, K. (2012). Autoimmune disease and subsequent digestive tract cancer by histology. Annals of Oncology, 23(4), 927-933. https://doi.org/10.1093/annonc/mdr333

Henkenberens, C., Toklu, H., Tamme, C., & Bruns, F. (2016). Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis. Anticancer Research, 36(6), 3173-3177.

Higham, C. E., & Faithfull, S. (2015). Bone Health and Pelvic Radiotherapy. Clinical Oncology (Royal College of Radiologists), 27(11), 668-678. https://doi.org/10.1016/j.clon.2015.07.006

Hodges, J. C., Das, P., Eng, C., Reish, A. G., Beddar, A. S., Delclos, M. E., . . . Crane, C. H. (2009). Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. International Journal of Radiation Oncology, Biology, Physics, 75(3), 791-794. https://doi.org/10.1016/j.ijrobp.2008.11.021

HPV-test gir enklere screening mot livmorhalskreft for 9 av 10 kvinner mellom 34 og 69 år. (2013). [nettdokument]. Oslo: Kreftregisteret. Hentet 23. aug. 2016, fra https://www.kreftregisteret.no/Generelt/Nyheter/HPV-test-gir-enklere-screening-mot-livmorhalskreft-for-9-av-10-kvinner-mellom-34-og-69-ar-/

HPV og HPV-vaksine. (2016). [nettside]. Oslo: Folkehelseinstituttet. Hentet 23. aug. 2016, fra https://www.fhi.no/sv/vaksine/hpv/

Humant papillomavirus (HPV), genitale infeksjoner - veileder for helsepersonell. (21. feb 2016). Smittevernveilederen [nettdokument]. Oslo: Folkehelseinstituttet. Hentet 23. aug 2016, fra https://www.fhi.no/nettpub/smittevernveilederen/sykdommer-a-a/humant-papillomavirus-hpv-genitale-/

Incrocci, L., & Jensen, P. T. (2013). Pelvic radiotherapy and sexual function in men and women. Journal of Sexual Medicine, 10 Suppl 1, 53-64. https://doi.org/10.1111/jsm.12010

International Clinical Guideline Group. (2012). International guidelines on vaginal dilation after pelvic radiotherapy. Woodstock, UK: Owen Mumford. Hentet fra http://www.ncsi.org.uk/wp-content/uploads/Inter-Best-Practice-Guide-Vaginal-Dilators-July-2012.pdf

Islami, F., Ferlay, J., Lortet-Tieulent, J., Bray, F., & Jemal, A. (2017). International trends in anal cancer incidence rates. International Journal of Epidemiology, 46(3), 924-938. https://doi.org/10.1093/ije/dyw276

James, R. D., Glynne-Jones, R., Meadows, H. M., Cunningham, D., Myint, A. S., Saunders, M. P., . . . Sebag-Montefiore, D. (2013). Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncology, 14(6), 516-524. https://doi.org/10.1016/s1470-2045(13)70086-x

Jeong, B. G., Kim, D. Y., & Kim, S. Y. (2013). Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum. Hepato-Gastroenterology, 60(123), 512-516. https://doi.org/10.5754/hge11293

Johnsson, A., Leon, O., Gunnlaugsson, A., Nilsson, P., & Hoglund, P. (2018). Determinants for local tumour control probability after radiotherapy of anal cancer. Radiotherapy and Oncology, 128(2), 380-386. https://doi.org/10.1016/j.radonc.2018.06.007

Julie, D. R., & Goodman, K. A. (2016). Advances in the Management of Anal Cancer. Current Oncology Reports, 18(3), 20. https://doi.org/10.1007/s11912-016-0503-3

Kachnic, L. A., Tsai, H. K., Coen, J. J., Blaszkowsky, L. S., Hartshorn, K., Kwak, E. L., . . . Hong, T. S. (2012). Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. International Journal of Radiation Oncology, Biology, Physics, 82(1), 153-158. https://doi.org/10.1016/j.ijrobp.2010.09.030

Kachnic, L. A., Winter, K., Myerson, R. J., Goodyear, M. D., Willins, J., Esthappan, J., . . . Willett, C. G. (2013). RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. International Journal of Radiation Oncology, Biology, Physics, 86(1), 27-33. https://doi.org/10.1016/j.ijrobp.2012.09.023

Kim, D. W., Byer, J., Kothari, N., Mahipal, A., Chang, Y. D., & Kim, R. D. (2017). EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology, 92(4), 190-196. https://doi.org/10.1159/000452766

Kim, J. H., Beets, G. L., Kim, M. J., Kessels, A. G., & Beets-Tan, R. G. (2004). High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? European Journal of Radiology, 52(1), 78-83. https://doi.org/10.1016/j.ejrad.2003.12.005

Kim, R., Byer, J., Fulp, W. J., Mahipal, A., Dinwoodie, W., & Shibata, D. (2014). Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology, 87(2), 125-132. https://doi.org/10.1159/000361051

Kim, S., François, E., André, T., Samalin, E., Jary, M., El Hajbi, F., . . . Borg, C. (2018). Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncology, 19(8), 1094-1106. https://doi.org/10.1016/s1470-2045(18)30321-8

Kochhar, R., Plumb, A. A., Carrington, B. M., & Saunders, M. (2012). Imaging of anal carcinoma. AJR: American Journal of Roentgenology, 199(3), W335-344. https://doi.org/10.2214/ajr.11.8027

Koh, D. M., Dzik-Jurasz, A., O'Neill, B., Tait, D., Husband, J. E., & Brown, G. (2008). Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. British Journal of Radiology, 81(962), 91-98. https://doi.org/10.1259/bjr/96187638

Krzowska-Firych, J., Lucas, G., Lucas, C., Lucas, N., & Pietrzyk, L. (2019). An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. Journal of infection and public health, 12(1), 1-6. https://doi.org/10.1016/j.jiph.2018.06.005

Kumar, S., Juresic, E., Barton, M., & Shafiq, J. (2010). Management of skin toxicity during radiation therapy: a review of the evidence. Journal of Medical Imaging and Radiation Oncology, 54(3), 264-279. https://doi.org/10.1111/j.1754-9485.2010.02170.x

Lam, J. U., Rebolj, M., Dugue, P. A., Bonde, J., von Euler-Chelpin, M., & Lynge, E. (2014). Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. Journal of Medical Screening, 21(1), 38-50. https://doi.org/10.1177/0969141314522454

Leon, O., Guren, M., Hagberg, O., Glimelius, B., Dahl, O., Havsteen, H., . . . Johnsson, A. (2014). Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology, 113(3), 352-358. https://doi.org/10.1016/j.radonc.2014.10.002

Leon, O., Guren, M. G., Radu, C., Gunnlaugsson, A., & Johnsson, A. (2015). Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. European Journal of Cancer, 51(18), 2740-2746. https://doi.org/10.1016/j.ejca.2015.08.029

Leon, O., Hagberg, O., & Johnsson, A. (2018). Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin. Acta Oncologica, 57(9), 1209-1215. https://doi.org/10.1080/0284186x.2018.1442931

Lepinoy, A., Lescut, N., Puyraveau, M., Caubet, M., Boustani, J., Lakkis, Z., . . . Bosset, J. F. (2015). Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiotherapy and Oncology, 116(2), 197-201. https://doi.org/10.1016/j.radonc.2015.07.050

Leve med kreft: nasjonal kreftstrategi (2018-2022). (2018). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/contentassets/266bf1eec38940888a589ec86d79da20/regjeringens_kreftstrategi_180418.pdf

Liem, X., Saad, F., & Delouya, G. (2015). A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis. Drugs, 75(13), 1471-1482. https://doi.org/10.1007/s40265-015-0443-5

Lim, F., & Glynne-Jones, R. (2011). Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treatment Reviews, 37(7), 520-532. https://doi.org/10.1016/j.ctrv.2011.02.003

Liu, Y., Sigel, K., & Gaisa, M. M. (2018). Human Papillomavirus Genotypes Predict Progression of Anal Low-Grade Squamous Intraepithelial Lesions. Journal of Infectious Diseases, 218(11), 1746-1752. https://doi.org/10.1093/infdis/jiy463

Lov om kommunale helse- og omsorgstjenester. LOV-2011-06-24-30.

Lukan, N., Ströbel, P., Willer, A., Kripp, M., Dinter, D., Mai, S., . . . Hofheinz, R. D. (2009). Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology, 77(5), 293-299. https://doi.org/10.1159/000259615

Lund, J. A., Sundstrom, S. H., Haaverstad, R., Wibe, A., Svinsaas, M., & Myrvold, H. E. (2004). Endoanal ultrasound is of little value in follow-up of anal carcinomas. Diseases of the Colon and Rectum, 47(6), 839-842. https://doi.org/10.1007/s10350-004-0529-8

Macaya, A., Munoz-Santos, C., Balaguer, A., & Barbera, M. J. (2012). Interventions for anal canal intraepithelial neoplasia. The Cochrane database of systematic reviews, 12, CD009244. https://doi.org/10.1002/14651858.CD009244.pub2

Machalek, D. A., Poynten, M., Jin, F., Fairley, C. K., Farnsworth, A., Garland, S. M., . . . Grulich, A. E. (2012). Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncology, 13(5), 487-500. https://doi.org/10.1016/s1470-2045(12)70080-3

Magdeburg, B., Fried, M., & Meyenberger, C. (1999). Endoscopic ultrasonography in the diagnosis, staging, and follow-up of anal carcinomas. Endoscopy, 31(5), 359-364. https://doi.org/10.1055/s-1999-35

Mai, S., Welzel, G., Ottstadt, M., Lohr, F., Severa, S., Prigge, E. S., . . . Reuschenbach, M. (2015). Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. International Journal of Radiation Oncology, Biology, Physics, 93(4), 819-827. https://doi.org/10.1016/j.ijrobp.2015.08.004

McMahon, C. J., Rofsky, N. M., & Pedrosa, I. (2010). Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology, 254(1), 31-46. https://doi.org/10.1148/radiol.2541090361

Meulendijks, D., Dewit, L., Tomasoa, N. B., van Tinteren, H., Beijnen, J. H., Schellens, J. H., & Cats, A. (2014). Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British Journal of Cancer, 111(9), 1726-1733. https://doi.org/10.1038/bjc.2014.467

Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., . . . Schellens, J. H. (2015). Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncology, 16(16), 1639-1650. https://doi.org/10.1016/s1470-2045(15)00286-7

Meulendijks, D., Tomasoa, N. B., Dewit, L., Smits, P. H., Bakker, R., van Velthuysen, M. L., . . . Cats, A. (2015). HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British Journal of Cancer, 112(8), 1358-1366. https://doi.org/10.1038/bjc.2015.20

Miles, T. (2012). International Guidelines on Vaginal Dilation after Pelvic Radiotherapy. Brook Hill, Woodstock, Oxon: Owen Mumford Ltd. Hentet fra http://www.ncsi.org.uk/wp-content/uploads/Inter-Best-Practice-Guide-Vaginal-Dilators-July-2012.pdf

Morris, V. K., Salem, M. E., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., . . . Eng, C. (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncology, 18(4), 446-453. https://doi.org/10.1016/s1470-2045(17)30104-3

Muehlbauer, P. M., Thorpe, D., Davis, A., Drabot, R., Rawlings, B. L., & Kiker, E. (2009). Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clinical Journal of Oncology Nursing, 13(3), 336-341. https://doi.org/10.1188/09.cjon.336-341

Muirhead, R., Partridge, M., & Hawkins, M. A. (2015). A tumor control probability model for anal squamous cell carcinoma. Radiotherapy and Oncology, 116(2), 192-196. https://doi.org/10.1016/j.radonc.2015.07.014

Musio, D., De Felice, F., Manfrida, S., Balducci, M., Meldolesi, E., Gravina, G. L., . . . Valentini, V. (2015). Squamous cell carcinoma of the rectum: The treatment paradigm. European Journal of Surgical Oncology, 41(8), 1054-1058. https://doi.org/10.1016/j.ejso.2015.03.239

Myerson, R. J., Garofalo, M. C., El Naqa, I., Abrams, R. A., Apte, A., Bosch, W. R., . . . Kachnic, L. A. (2009). Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. International Journal of Radiation Oncology, Biology, Physics, 74(3), 824-830. https://doi.org/10.1016/j.ijrobp.2008.08.070

Nasjonal handlingsplan for kreft 2015-2017. (2015). (IS-2298). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/publikasjoner/nasjonal-handlingsplan-for-kreft-2015-2017

Nasjonal helse- og sykehusplan (2016−2019). (2015). (Meld. St. 11 (2015–2016)). Oslo: Helse- og omsorgsdepartemenetet. Hentet fra https://www.regjeringen.no/contentassets/7b6ad7e0ef1a403d97958bcb34478609/no/pdfs/stm201520160011000dddpdfs.pdf

Nasjonal strategi for kreftområdet 2006-2009. (2006). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf

Ng, M., Ho, H., Skelton, J., Guerrieri, M., Guiney, M., Chao, M., . . . Melven, L. (2018). Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. Clinical Oncology (Royal College of Radiologists), 30(10), 634-641. https://doi.org/10.1016/j.clon.2018.07.020

Ng, M., Leong, T., Chander, S., Chu, J., Kneebone, A., Carroll, S., . . . Kachnic, L. (2012). Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1455-1462. https://doi.org/10.1016/j.ijrobp.2011.12.058

Nguyen, B. T., Joon, D. L., Khoo, V., Quong, G., Chao, M., Wada, M., . . . Scott, A. (2008). Assessing the impact of FDG-PET in the management of anal cancer. Radiotherapy and Oncology, 87(3), 376-382. https://doi.org/10.1016/j.radonc.2008.04.003

Nigro, N. D. (1984). An evaluation of combined therapy for squamous cell cancer of the anal canal. Diseases of the Colon and Rectum, 27(12), 763-766.

Nigro, N. D., Vaitkevicius, V. K., & Considine, B., Jr. (1974). Combined therapy for cancer of the anal canal: a preliminary report. Diseases of the Colon and Rectum, 17(3), 354-356.

Nilsen, E., Alfsen, C. G., Feiring, B., Skjeldestad, F. E., Steen, R., & Sæterdal, I. (2007). Vaksiner mot humant papillomavirus (HPV): vurdering av effekt av profylaktiske HPV-vaksiner (Rapport fra Kunnskapssenteret Nr 5-2007). Oslo: Nasjonalt kunnskapssenter for helsetjenesten. Hentet fra http://www.kunnskapssenteret.no/publikasjoner/vaksiner-mot-humant-papillomavirus-hpv-vurdering-av-effekt-av-profylaktiske-hpv-vaksiner

Nilsson, M. P., Nilsson, E. D., Johnsson, A., Leon, O., Gunnlaugsson, A., & Scherman, J. (2020). Patterns of recurrence in anal cancer: a detailed analysis. Radiation Oncology (London, England), 15(1), 125. https://doi.org/10.1186/s13014-020-01567-7

Nilsson, P. J., Svensson, C., Goldman, S., & Glimelius, B. (2002). Salvage abdominoperineal resection in anal epidermoid cancer. British Journal of Surgery, 89(11), 1425-1429. https://doi.org/10.1046/j.1365-2168.2002.02231.x

Otto, S. D., Lee, L., Buhr, H. J., Frericks, B., Hocht, S., & Kroesen, A. J. (2009). Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. Journal of Gastrointestinal Surgery, 13(7), 1292-1298. https://doi.org/10.1007/s11605-009-0870-2

Parikh, J., Shaw, A., Grant, L. A., Schizas, A. M., Datta, V., Williams, A. B., & Griffin, N. (2011). Anal carcinomas: the role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up. European Radiology, 21(4), 776-785. https://doi.org/10.1007/s00330-010-1980-7

Peron, J., Bylicki, O., Laude, C., Martel-Lafay, I., Carrie, C., & Racadot, S. (2015). Nonoperative management of squamous-cell carcinoma of the rectum. Diseases of the Colon and Rectum, 58(1), 60-64. https://doi.org/10.1097/dcr.0000000000000218

Pineda, C. E., & Welton, M. L. (2009). Management of anal squamous intraepithelial lesions. Clinics in Colon and Rectal Surgery, 22(2), 94-101. https://doi.org/10.1055/s-0029-1223840

Rao, S., Guren, M. G., Khan, K., Brown, G., Renehan, A. G., Steigen, S. E., . . . Arnold, D. (2021). Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Jun 22 Epub ahead of print. https://doi.org/10.1016/j.annonc.2021.06.015

Rao, S., Sclafani, F., Eng, C., Adams, R. A., Guren, M. G., Sebag-Montefiore, D., . . . Cunningham, D. (2020). International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology, 38(22), 2510-2518. https://doi.org/10.1200/jco.19.03266

Renehan, A. G., & O'Dwyer, S. T. (2011). Management of local disease relapse. Colorectal Disease, 13 Suppl 1, 44-52. https://doi.org/10.1111/j.1463-1318.2010.02500.x

Renehan, A. G., Saunders, M. P., Schofield, P. F., & O'Dwyer, S. T. (2005). Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. British Journal of Surgery, 92(5), 605-614. https://doi.org/10.1002/bjs.4908

Richel, O., de Vries, H. J., van Noesel, C. J., Dijkgraaf, M. G., & Prins, J. M. (2013). Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncology, 14(4), 346-353. https://doi.org/10.1016/s1470-2045(13)70067-6

Roach, S. C., Hulse, P. A., Moulding, F. J., Wilson, R., & Carrington, B. M. (2005). Magnetic resonance imaging of anal cancer. Clinical Radiology, 60(10), 1111-1119. https://doi.org/10.1016/j.crad.2005.05.008

Rodel, F., Wieland, U., Fraunholz, I., Kitz, J., Rave-Frank, M., Wolff, H. A., . . . Rodel, C. (2015). Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. International Journal of Cancer, 136(2), 278-288. https://doi.org/10.1002/ijc.28979

Rogers, J. E., & Eng, C. (2017). Pharmacotherapy of Anal Cancer. Drugs, 77(14), 1519-1530. https://doi.org/10.1007/s40265-017-0792-3

Salerno, G., Daniels, I., Heald, R. J., Brown, G., & Moran, B. J. (2004). Management and imaging of low rectal carcinoma. Surgical Oncology, 13(2-3), 55-61. https://doi.org/10.1016/j.suronc.2004.09.013

Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. (2013). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/contentassets/07cd14ff763444a3997de1570b85fad1/kreftstrategien_2013.pdf

Scholefield, J. H., Castle, M. T., & Watson, N. F. (2005). Malignant transformation of high-grade anal intraepithelial neoplasia. British Journal of Surgery, 92(9), 1133-1136. https://doi.org/10.1002/bjs.4994

Sclafani, F., & Rao, S. (2018). Systemic Therapies for Advanced Squamous Cell Anal Cancer. Current Oncology Reports, 20(7), 53. https://doi.org/10.1007/s11912-018-0698-6

Sekhar, H., Malcomson, L., Kochhar, R., Sperrin, M., Alam, N., Chakrbarty, B., . . . Renehan, A. G. (2020). Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014). British Journal of Cancer, 122(6), 749-758. https://doi.org/10.1038/s41416-019-0689-x

Seneffekter etter kreftbehandling: faglige råd. (2017). (IS-2551). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/1276/Seneffekter%20etter%20kreftbehandling-IS-2551.pdf

Serup-Hansen, E., Linnemann, D., Skovrider-Ruminski, W., Hogdall, E., Geertsen, P. F., & Havsteen, H. (2014). Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. Journal of Clinical Oncology, 32(17), 1812-1817. https://doi.org/10.1200/jco.2013.52.3464

Shida, D., Kanemitsu, Y., Hamaguchi, T., & Shimada, Y. (2019). Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Japanese Journal of Clinical Oncology, 49(4), 321-328. https://doi.org/10.1093/jjco/hyy198

Shiels, M. S., Pfeiffer, R. M., Chaturvedi, A. K., Kreimer, A. R., & Engels, E. A. (2012). Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. Journal of the National Cancer Institute, 104(20), 1591-1598. https://doi.org/10.1093/jnci/djs371

Slørdahl, K. S., Klotz, D., Olsen, J., Skovlund, E., Undseth, C., Abildgaard, H. L., . . . Guren, M. G. (2021). Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncologica, Dec 15 [Epub ahead of print]. https://doi.org/10.1080/0284186x.2021.1918763

Sodergren, S. C., Johnson, C. D., Gilbert, A., Tomaszewski, K. A., Chu, W., Chung, H. T., . . . Vassiliou, V. (2018). Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. Radiotherapy and Oncology, 126(2), 222-228. https://doi.org/10.1016/j.radonc.2017.11.018

Sodergren, S. C., Vassiliou, V., Dennis, K., Tomaszewski, K. A., Gilbert, A., Glynne-Jones, R., . . . Johnson, C. D. (2015). Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Supportive Care in Cancer, 23(12), 3613-3623. https://doi.org/10.1007/s00520-015-2879-2

Spithoff, K., Cummings, B., Jonker, D., & Biagi, J. J. (2014). Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. Clinical Oncology (Royal College of Radiologists), 26(8), 473-487. https://doi.org/10.1016/j.clon.2014.03.005

Statistik om analkræft. (12. august 2019). [nettside]. København: Kræftens Bekæmpelse. Hentet 6. april 2021, fra https://www.cancer.dk/analkraeft-analcancer/statistik-analkraeft/

Stoker, J., Rociu, E., Wiersma, T. G., & Lameris, J. S. (2000). Imaging of anorectal disease. British Journal of Surgery, 87(1), 10-27. https://doi.org/10.1046/j.1365-2168.2000.01338.x

Sturgeon, J. D., Crane, C. H., Krishnan, S., Minsky, B. D., Skibber, J. M., Rodriguez-Bigas, M. A., . . . Das, P. (2017). Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. American Journal of Clinical Oncology, 40(2), 163-166. https://doi.org/10.1097/coc.0000000000000126

Sun, G., Dong, X., Tang, X., Qu, H., Zhang, H., & Zhao, E. (2018). The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. Oncotarget, 9(8), 8081-8088. https://doi.org/10.18632/oncotarget.23545

Sunesen, K. G., Norgaard, M., Thorlacius-Ussing, O., & Laurberg, S. (2010). Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. International Journal of Cancer, 127(3), 675-684. https://doi.org/10.1002/ijc.25080

Tahir, A. R., Westhuyzen, J., Dass, J., Collins, M. K., Webb, R., Hewitt, S., . . . McKay, M. (2015). Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia's largest study. Asia-Pacific Journal of Clinical Oncology, 11(1), 68-77. https://doi.org/10.1111/ajco.12289

Taylor, A., Rockall, A. G., Reznek, R. H., & Powell, M. E. (2005). Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 63(5), 1604-1612. https://doi.org/10.1016/j.ijrobp.2005.05.062

The Royal College of Radiologists. (20019). The timely delivery of radical radiotherapy: standards and guidelines for the management of unscheduled treatment interruptions (4. utg.). London: The Royal College of Radiologist. Hentet fra https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfco191_radiotherapy-treatment-interruptions.pdf

Thind, G., Johal, B., Follwell, M., & Kennecke, H. F. (2014). Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiation Oncology (London, England), 9, 124. https://doi.org/10.1186/1748-717x-9-124

TNM Classification of Malignant Tumours. (2017). (8. utg.). New York: John Wiley & Sons.

Vanneste, B. G., Van De Voorde, L., de Ridder, R. J., Van Limbergen, E. J., Lambin, P., & van Lin, E. N. (2015). Chronic radiation proctitis: tricks to prevent and treat. International Journal of Colorectal Disease, 30(10), 1293-1303. https://doi.org/10.1007/s00384-015-2289-4

Wade, D. S., Herrera, L., Castillo, N. B., & Petrelli, N. J. (1989). Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surgery, Gynecology and Obstetrics, 169(3), 238-242.

Watson, A. J., Smith, B. B., Whitehead, M. R., Sykes, P. H., & Frizelle, F. A. (2006). Malignant progression of anal intra-epithelial neoplasia. ANZ Journal of Surgery, 76(8), 715-717. https://doi.org/10.1111/j.1445-2197.2006.03837.x

Wells, I. T., & Fox, B. M. (2012). PET/CT in anal cancer - is it worth doing? Clinical Radiology, 67(6), 535-540. https://doi.org/10.1016/j.crad.2011.10.030

WHO Classification of Tumours of the Digestive System. (2010). (4. utg.). Lyon: International Agency for Research on Cancer.

Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., . . . Hurria, A. (2014). International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. Journal of Clinical Oncology, 32(24), 2595-2603. https://doi.org/10.1200/jco.2013.54.8347

Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., & Koutsky, L. A. (2006). Condom use and the risk of genital human papillomavirus infection in young women. New England Journal of Medicine, 354(25), 2645-2654. https://doi.org/10.1056/NEJMoa053284

Zidar, N., Langner, C., Odar, K., Hošnjak, L., Kamaradova, K., Daum, O., . . . Poljak, M. (2017). Anal verrucous carcinoma is not related to infection with human papillomaviruses and should be distinguished from giant condyloma (Buschke-Lowenstein tumour). Histopathology, 70(6), 938-945. https://doi.org/10.1111/his.13158

zur Hausen, H. (2000). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute, 92(9), 690-698. https://doi.org/10.1093/jnci/92.9.690

Aass, N., Haugne, D. F., Rosland, J. H., HJordhøy, M., Dønnem, T., & Knudsen, A. K. (2015). Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen (5. utg.). (IS-2285). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen

Siste faglige endring: 02. juli 2017